Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12, 1529-1534
eCollection

Simvastatin Improves the Eradication Rate of Helicobacter pylori: Upper Egypt Experience

Affiliations

Simvastatin Improves the Eradication Rate of Helicobacter pylori: Upper Egypt Experience

Amro Metwaly Hassan et al. Infect Drug Resist.

Abstract

Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate.

Keywords: clarithromycin resistance; eradication of H. Pylori; simvastatin; standard triple therapy.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart of the studied patients.

Similar articles

See all similar articles

References

    1. Hooi KJY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori Infection: systematicReview and meta-analysis. Gastroenterology. 2017;153:420–429. doi:10.1053/j.gastro.2017.04.022 - DOI - PubMed
    1. Ghotaslou R, Ebrahimzadeh Leylabadlo H, Mohammadzadeh Asl Y. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol. 2015;5(3):164–174. doi:10.5662/wjm.v5.i3.164 - DOI - PMC - PubMed
    1. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol. 2012;47:609–618. doi:10.1007/s00535-012-0592-1 - DOI - PubMed
    1. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population. Gut. 2018;67(12):2092–2096. doi:10.1136/gutjnl-2017-315363 - DOI - PubMed
    1. Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. J Glob Antimicrob Resist. 2018;14:111–117. doi:10.1016/j.jgar.2018.03.005 - DOI - PubMed

LinkOut - more resources

Feedback